Sernova and Seraxis close $11.2M to fund diabetes cell-therapy merger
What's the deal? Seraxis HoldingsDealroom has a profile for this one. Try Dealroom → has closed a US$11.2 million convertible note financing to fund its merger with Sernova BiotherapeuticsDealroom has a profile for this one. Try Dealroom →, forming a new company called BetaNova BiotherapeuticsDealroom has a profile for this one. Try Dealroom →. The round, which topped its US$10 million target, drew backing from insiders, existing shareholders, and new investors.
Who's in? Participants include Arlo Investments and Dr. Steven Sangha, alongside management from both companies — Sernova's Jonathan Rigby, James ParsonsDealroom has a profile for this one. Try Dealroom →, Marylyn Rigby, and David BurkeDealroom has a profile for this one. Try Dealroom →, plus Seraxis's Will Rust and Carole Welsch.
What's the endgame? BetaNova aims to develop a cell-replacement therapy for type 1 diabetes. It will combine Seraxis's stem cell-derived pancreatic islet programs and cGMP manufacturing with Sernova's Cell Pouch Bio-hybrid Organ, an implantation device.
Where the money goes. Proceeds will support manufacturing of lead candidate SR-02, patient enrollment for a Phase 1/2 trial this quarter, and first dosing in Q1 2027 under an FDA-cleared application. The company also plans to advance a next-generation program, SR-03, toward an application filing in the second half of 2027.
Why now? The two firms signed their merger agreement on September 7, 2026, with shareholders of each expected to own roughly 50% of BetaNova. The financing locks in capital ahead of the clinic, and the company is targeting Nasdaq listing readiness for Q1 2027.
"This financing puts capital directly behind the milestones we have outlined for BetaNova as we passionately advance towards a potential functional cure for people living with T1D," said Jonathan Rigby, president and chief executive officer of Sernova.
What could go wrong? The merger remains subject to required approvals and customary closing conditions, and the Nasdaq listing depends on meeting applicable requirements. The notes are only expected to convert into BetaNova stock once the deal completes.
The signal: The raise sits around the 90th percentile for convertible health rounds in the US, a sign of investor appetite for late-stage diabetes cell therapy. With dosing slated for early 2027, BetaNova is betting it can enter a competitive field at the point where data starts to matter.
Read more: pr.southjordanjournal.com
Image credit: Seraxis
